Physician profile
Beth Moreland
NPI 1407274780
$7,970.62
in general payments reported to CMS, 2019-2025
53 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,281 · 2022: $634 · 2023: $1,630 · 2024: $2,494 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,041 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,041.24 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $771.66 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $688.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $664.00 | 2021-2025 | |
| Lilly USA, LLC | $660.56 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $501.19 | 2021-2025 | Otezla, Repatha, Evenity |
| Antares Pharma, INC. | $227.85 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.54 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Daiichi Sankyo INC. | $155.68 | 2024-2025 | Injectafer |
| Nevro Corp. | $149.54 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $129.53 | 2021-2023 | Belsomra |
| Sanofi-Aventis U.S. LLC | $125.10 | 2021-2022 | |
| Glaxosmithkline, LLC. | $123.26 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Collegium Pharmaceutical, INC. | $121.06 | 2021-2025 | Jornay Pm |
| Sumitomo Pharma America, INC. | $120.31 | 2023-2024 | Gemtesa |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Moreland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.